Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends, European urology, vol.71, issue.1, pp.96-108, 2017. ,
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012, European journal of cancer, vol.49, issue.6, pp.1374-403, 1990. ,
Is there a gender effect in bladder cancer? A population-based study of practice and outcomes, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, vol.9, issue.7-8, pp.269-74, 2015. ,
The impact of female gender on bladder cancer-specific death risk after radical cystectomy: a meta-analysis of 27,912 patients. International urology and nephrology, vol.47, pp.951-959, 2015. ,
Mechanisms of disease: The epidemiology of bladder cancer, Nature clinical practice Urology, vol.3, issue.6, pp.327-367, 2006. ,
Association between smoking and risk of bladder cancer among men and women, Jama, vol.306, issue.7, pp.737-782, 2011. ,
Tobacco smoking and cancer: a meta-analysis, International journal of cancer Journal international du cancer, vol.122, issue.1, pp.155-64, 2008. ,
Epidemiology and risk factors of urothelial bladder cancer, European urology, vol.63, issue.2, pp.234-275, 2013. ,
Bladder cancer among hairdressers: a meta-analysis. Occupational and environmental medicine, vol.67, pp.351-359, 2010. ,
Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers: an updated systematic review and a meta-analysis to, Archives of toxicology, vol.88, issue.8, pp.1479-90, 2014. ,
Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study, BMC cancer, vol.15, p.720, 2015. ,
The association between physical activity and bladder cancer: systematic review and meta-analysis, British journal of cancer, vol.110, issue.7, pp.1862-70, 2014. ,
Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer, The Journal of urology, vol.174, issue.1, pp.10-11, 2005. ,
Incidence of secondary cancer development after high-dose intensity-modulated radiotherapy and image-guided brachytherapy for the treatment of localized prostate cancer, International journal of radiation oncology, vol.83, issue.3, pp.953-962, 2012. ,
Bilharziasis and bladder cancer: a time trend analysis of 9843 patients, Journal of the Egyptian National Cancer Institute, vol.19, issue.2, pp.158-62, 2007. ,
Bladder cancer and arsenic through drinking water: a systematic review of epidemiologic evidence, Journal of environmental science and health Part A, Toxic/hazardous substances & environmental engineering, vol.48, issue.14, pp.1764-75, 2013. ,
Risk of bladder cancer associated with family history of cancer: do lowpenetrance polymorphisms account for the increase in risk? Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol.16, pp.1595-600, 2007. ,
,
, Genome-wide association study identifies multiple loci associated with bladder cancer risk, Human molecular genetics, vol.23, issue.5, pp.1387-98, 2014.
Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.19, issue.3, pp.666-75, 2001. ,
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials, European urology, vol.49, issue.3, pp.75-82, 2006. ,
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guerin, European urology, vol.69, issue.1, pp.60-69, 2016. ,
Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis, Cancer epidemiology, vol.37, issue.3, pp.219-244, 2013. ,
Management of elderly patients with urothelial carcinoma of the bladder: guideline concordance and predictors of overall survival, BJU international, vol.106, issue.9, pp.1324-1333, 2010. ,
Gender, racial and age differences in bladder cancer incidence and mortality, Urologic oncology, vol.22, issue.2, pp.86-92, 2004. ,
Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry, The Journal of urology, vol.183, issue.3, pp.915-935, 2010. ,
The Prognostic Impact of Histopathological Variants in Patients with Advanced Urothelial Carcinoma, PloS one, vol.10, issue.6, p.129268, 2015. ,
Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy, Virchows Archiv : an international journal of pathology, vol.469, issue.3, pp.339-383, 2016. ,
Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy, BMC cancer, vol.13, p.71, 2013. ,
Lymph node metastases in patients with urothelial carcinoma variants: influence of the specific variant on nodal histology, Urologic oncology, vol.33, issue.1, pp.3-9, 2015. ,
Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study, The Journal of urology, vol.171, issue.1, pp.139-183, 2004. ,
Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival, The American journal of surgical pathology, vol.24, issue.7, pp.980-987, 2000. ,
The management of superficial bladder cancer, Nature clinical practice Urology, vol.4, issue.5, pp.254-60, 2007. ,
Cystectomy for bladder cancer: a contemporary series, The Journal of urology, vol.165, issue.4, pp.1111-1117, 2001. ,
Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.23, issue.10, pp.2358-65, 2005. ,
Incidence of occult lymph-node metastasis missed by standard pathological examination in patients with bladder cancer undergoing radical cystectomy, Scandinavian journal of urology and nephrology, vol.45, issue.6, pp.419-443, 2011. ,
Intravesical tumor involvement of the trigone is associated with nodal metastasis in patients undergoing radical cystectomy, Urology, vol.84, issue.5, pp.1147-51, 2014. ,
Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice, Urologic oncology, vol.32, issue.7, pp.1078-87, 2014. ,
Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. The American journal of surgical pathology, vol.38, pp.20-34, 2014. ,
Clinical cancer research : an official journal of the American Association for Cancer Research, vol.18, pp.3377-86, 2012. ,
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer, Cell, vol.171, issue.3, pp.540-56, 2017. ,
Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy, Cancer cell, vol.25, issue.2, pp.152-65, 2014. ,
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up, Medical Oncology / ESMO, vol.25, issue.3, pp.40-48, 2014. ,
Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy, The Journal of urology, vol.163, issue.6, pp.1693-1699, 2000. ,
CT urography: definition, indications and techniques. A guideline for clinical practice, European radiology, vol.18, issue.1, pp.4-17, 2008. ,
Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT, European radiology, vol.6, issue.2, pp.129-162, 1996. ,
Bladder cancer: evaluation of staging accuracy using dynamic MRI, Clinical radiology, vol.66, issue.12, pp.1140-1145, 2011. ,
MR imaging of the bladder. Magnetic resonance imaging clinics of North America, vol.12, pp.545-55, 2004. ,
Metastases in normal-sized pelvic lymph nodes: detection with diffusion-weighted MR imaging, Radiology, vol.273, issue.1, pp.125-160, 2014. ,
Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis, European journal of radiology, vol.81, issue.9, pp.2411-2417, 2012. ,
Is whole-body fluorine-18 fluorodeoxyglucose PET/CT plus additional pelvic images (oral hydration-voiding-refilling) useful for detecting recurrent bladder cancer? Annals of nuclear medicine, vol.26, pp.571-578, 2012. ,
Secondary malignant involvement of gynecologic organs in radical cystectomy specimens in women: is it mandatory to remove these organs routinely?, The Journal of urology, vol.172, issue.3, pp.885-892, 2004. ,
Prostate sparing cystectomy for bladder cancer: 20-year single center experience, The Journal of urology, vol.191, issue.5, pp.1250-1255, 2014. ,
Seminal-sparing cystectomy: technical evolution and results over a 20-year period, Urology, vol.83, issue.4, pp.856-61, 2014. ,
Prostate-sparing cystectomy: a review of the oncologic and functional outcomes, Urologic oncology, vol.27, issue.5, pp.466-72, 2009. ,
Laparoscopic versus open radical cystectomy in bladder cancer: a systematic review and meta-analysis of comparative studies, PloS one, vol.9, issue.5, p.95667, 2014. ,
Impact of suboptimal neoadjuvant chemotherapy on peri-operative outcomes and survival after robot-assisted radical cystectomy: a multicentre multinational study, BJU international, vol.119, issue.4, pp.605-616, 2017. ,
A randomized trial of robot-assisted laparoscopic radical cystectomy. The New England journal of medicine, vol.371, pp.389-90, 2014. ,
Current status of robotic assisted radical cystectomy with intracorporeal ileal neobladder for bladder cancer, Journal of surgical oncology, vol.112, issue.4, pp.427-436, 2015. ,
Best practices in robot-assisted radical cystectomy and urinary reconstruction: recommendations of the Pasadena Consensus Panel, European urology, vol.67, issue.3, pp.363-75, 2015. ,
Treatment of muscle-invasive bladder cancer: A systematic review, Cancer, vol.122, issue.6, pp.842-51, 2016. ,
Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study, European urology, vol.60, issue.5, pp.946-52, 2011. ,
Benefit of bladder and upper urinary tract urothelial tumors lymph node dissection: review from the Bladder Cancer Committee of the French National Association of Urology ,
, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, vol.22, pp.380-387, 2012.
The impact of the extent of lymphadenectomy on oncologic outcomes in patients undergoing radical cystectomy for bladder cancer: a systematic review, European urology, vol.66, issue.6, pp.1065-77, 2014. ,
Anatomic basis for lymph node counts as measure of lymph node dissection extent: a cadaveric study, Urology, vol.81, issue.2, pp.358-63, 2013. ,
Stagespecific impact of extended versus standard pelvic lymph node dissection in radical cystectomy, International journal of urology : official journal of the Japanese Urological Association, vol.20, issue.4, pp.390-397, 2013. ,
Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and survival, International journal of urology : official journal of the Japanese Urological Association, vol.19, issue.1, pp.39-47, 2012. ,
Urinary functional outcome following radical cystoprostatectomy and ileal neobladder reconstruction in male patients, The Journal of urology, vol.189, issue.5, pp.1782-1790, 2013. ,
After cystectomy, is it justified to perform a bladder replacement for patients with lymph node positive bladder cancer?, European urology, vol.42, issue.4, pp.344-353, 2002. ,
Bladder substitution. Current opinion in urology, vol.9, pp.241-246, 1999. ,
Impact of the use of bowel for urinary diversion on perioperative complications and 90-day mortality in patients aged 75 years or older, Urologia internationalis, vol.94, issue.4, pp.394-400, 2015. ,
Complications and quality of life in elderly patients with several comorbidities undergoing cutaneous ureterostomy with single stoma or ileal conduit after radical cystectomy, BJU international, vol.118, issue.4, pp.521-527, 2016. ,
,
, Gan to kagaku ryoho Cancer & chemotherapy, vol.28, issue.12, pp.1838-1882, 2001.
, Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis, Lancet, vol.361, issue.9373, pp.1927-1961, 2003.
, Neoadjuvant cisplatin for advanced bladder cancer. The Cochrane database of systematic reviews, p.1426, 2000.
, WITHDRAWN: Neoadjuvant cisplatin for advanced bladder cancer. The Cochrane database of systematic reviews, p.1426, 2011.
, Neoadjuvant chemotherapy for invasive bladder cancer. The Cochrane database of systematic reviews, p.5246, 2005.
, Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) metaanalysis collaboration, European urology, vol.48, issue.2, pp.202-207, 2005.
Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer-Nordic cystectomy trial 2, Scandinavian journal of urology and nephrology, vol.36, issue.6, pp.419-444, 2002. ,
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. The New England journal of medicine, vol.349, pp.859-66, 2003. ,
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer, European urology, vol.61, issue.6, pp.1229-1267, 2012. ,
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer, European urology, vol.71, issue.3, pp.462-75, 2017. ,
Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer, Expert opinion on drug metabolism & toxicology, vol.11, issue.5, pp.731-773, 2015. ,
Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209, Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, vol.25, issue.6, pp.1192-1200, 2014. ,
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer, European urology, vol.62, issue.3, pp.523-556, 2012. ,
Neoadjuvant CMV chemotherapy plus radical cystectomy in locally advanced bladder cancer: the impact of pathologic response on long-term results, Tumori, vol.82, issue.5, pp.463-472, 1996. ,
Current and future perspectives in advanced bladder cancer: is there a new standard? Seminars in oncology, vol.29, pp.3-14, 2002. ,
Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder, Urology, vol.79, issue.2, pp.384-90, 2012. ,
Neoadjuvant chemotherapy with gemcitabine/cisplatin vs ,
, methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California, Urologic oncology, vol.31, issue.8, pp.1737-1780, 2013.
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer, Cancer, vol.121, issue.15, pp.2586-93, 2015. ,
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer, European urology, vol.67, issue.2, pp.241-250, 2015. ,
Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder, Cancer, vol.118, issue.16, pp.3920-3927, 2012. ,
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.19, issue.10, pp.2638-2684, 2001. ,
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours, European journal of cancer, vol.42, issue.1, pp.50-54, 1990. ,
The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy, International journal of clinical oncology, vol.22, issue.1, pp.159-65, 2017. ,
Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscleinvasive bladder cancer, Urologic oncology, vol.32, issue.8, pp.1172-1179, 2014. ,
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, openlabel, randomised phase 3 trial. The Lancet Oncology, vol.16, pp.76-86, 2015. ,
The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Annals of oncology : official journal of the European Society for, Medical Oncology / ESMO, vol.11, issue.7, pp.851-857, 2000. ,
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial, Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, vol.23, issue.3, pp.695-700, 2012. ,
Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials, European urology, vol.66, issue.1, pp.42-54, 2014. ,
The role of perioperative chemotherapy in the treatment of urothelial cancer, The oncologist, vol.11, issue.6, pp.630-670, 2006. ,
Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.34, issue.8, pp.825-857, 2016. ,
, Adjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration, European urology, vol.48, issue.2, pp.99-201, 2005.
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95), Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.23, issue.22, pp.4963-74, 2005. ,
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine, Cancer, vol.95, issue.4, pp.751-758, 2002. ,
The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study, European urology, vol.66, issue.3, pp.561-569, 2014. ,
Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity, BJU international, vol.114, issue.2, pp.221-229, 2014. ,
Perioperative complications after neoadjuvant chemotherapy and radical cystectomy for bladder cancer. The Canadian journal of urology, vol.21, pp.7259-65, 2014. ,
Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings, Urologic oncology, vol.33, issue.9, pp.386-387, 2015. ,
An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma, The Journal of urology, vol.169, issue.1, pp.110-115, 2003. ,
Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis, Cancer, vol.115, issue.5, pp.988-96, 2009. ,
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome, BJU international, vol.100, issue.5, pp.1015-1035, 2007. ,
Prevention and management of complications following radical cystectomy for bladder cancer, European urology, vol.57, issue.6, pp.983-1001, 2010. ,
Complications after robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium, European urology, vol.64, issue.1, pp.52-59, 2013. ,
Complications for radical cystectomy. Impact of the American Society of Anesthesiologists score, European urology, vol.39, issue.1, pp.79-84, 2001. ,
Results from three municipal hospitals regarding radical cystectomy on elderly patients, International braz j urol : official journal of the Brazilian Society of Urology, vol.33, issue.6, pp.764-73, 2007. ,
Urinary diversions after cystectomy: the association of clinical factors, complications and functional results of four different diversions, European urology, vol.53, issue.4, pp.834-876, 2008. ,
Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer. The Canadian journal of urology, vol.22, pp.7865-75, 2015. ,
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, Journal of chronic diseases, vol.40, issue.5, pp.373-83, 1987. ,
Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study, Annals of surgical oncology, vol.19, issue.1, pp.309-326, 2012. ,
Predictive capacity of four comorbidity indices estimating perioperative mortality after radical cystectomy for urothelial carcinoma of the bladder, BJU international, vol.110, issue.6, pp.222-229, 2012. ,
The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer, BJU international, vol.113, issue.6, pp.887-93, 2014. ,
The impact of co-morbid disease on cancer control and survival following radical cystectomy, The Journal of urology, vol.169, issue.1, pp.105-114, 2003. ,
Radical cystectomy in patients older than 75 years: assessment of morbidity and mortality, European urology, vol.39, issue.5, pp.525-534, 2001. ,
Preoperative serum albumin is associated with mortality and complications after radical cystectomy, BJU international, vol.113, issue.6, pp.918-941, 2014. ,
Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer, Cancer, vol.112, issue.11, pp.2384-92, 2008. ,
Predicting the probability of 90-day survival of elderly patients with bladder cancer treated with radical cystectomy, The Journal of urology, vol.186, issue.3, pp.829-863, 2011. ,
Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS((R))) society recommendations, Clinical nutrition, vol.32, issue.6, pp.879-87, 2013. ,
A new concept for early recovery after surgery for patients undergoing radical cystectomy for bladder cancer: results of a prospective randomized study, The Journal of urology, vol.191, issue.2, pp.335-375, 2014. ,
,
, Postoperative Pain Management after Radical Cystectomy: Comparing Traditional versus Enhanced Recovery Protocol Pathway, The Journal of urology, vol.194, issue.5, pp.1209-1222, 2015.
Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial, European urology, vol.66, issue.2, pp.265-72, 2014. ,
Alvimopan, a peripherally acting mu-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial, The Journal of urology, vol.191, issue.6, pp.1721-1728, 2014. ,
Effects of Immunonutrition for Cystectomy on Immune Response and Infection Rates: A Pilot Randomized Controlled Clinical Trial, European urology, vol.69, issue.3, pp.389-92, 2016. ,
A controlled trial of inpatient and outpatient geriatric evaluation and management. The New England journal of medicine, vol.346, pp.905-917, 2002. ,
Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study, PloS one, vol.9, issue.12, p.115060, 2014. ,
Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma, Clinical genitourinary cancer, vol.14, issue.1, pp.59-65, 2016. ,
Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis, European urology, vol.65, issue.2, pp.350-357, 2014. ,
Primary cisplatin, methotrexate and vinblastine chemotherapy with selective bladder preservation for muscle invasive carcinoma of the bladder: long-term followup of a prospective study, The Journal of urology, vol.167, issue.6, pp.2413-2421, 2002. ,
Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy, Urology, vol.64, issue.3, pp.488-93, 2004. ,
Can patient selection for bladder preservation be based on response to chemotherapy?, Cancer, vol.97, issue.7, pp.1644-52, 2003. ,